4-ketoproline: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
4-oxo-L-proline : The L-enantiomer of 4-oxoproline. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 107541 |
| CHEBI ID | 16821 |
| SCHEMBL ID | 190463 |
| MeSH ID | M0111745 |
| Synonym |
|---|
| CHEBI:16821 |
| (2s)-4-oxopyrrolidine-2-carboxylic acid |
| 4-ketoproline |
| C01877 , |
| 4-oxoproline , |
| 4347-18-6 |
| 4-oxo-l-proline |
| AKOS006285565 |
| proline, 4-oxo- |
| 4-oxo-proline |
| AKOS015995285 |
| einecs 224-409-0 |
| SCHEMBL190463 |
| 4-keto-l-proline |
| 4-keto-(l)-proline |
| HFXAFXVXPMUQCQ-BYPYZUCNSA-N |
| (s)-4-oxopyrrolidine-2-carboxylic acid |
| l-proline, 4-oxo- |
| (s)-4-ozopyrrolidine-2-carboxylic acid |
| CS-0271190 |
| EN300-260257 |
| DTXSID20942014 |
| Q27102095 |
| (s)-4-oxopyrrolidine-2-carboxylicacid |
| A851219 |
| D87765 |
| BS-52241 |
| mfcd07367800 |
| Class | Description |
|---|---|
| amino acid zwitterion | The zwitterionic form of an amino acid having a negatively charged carboxyl group and a positively charged amino group. |
| 4-oxoproline | The 4-isomer of oxoproline. |
| L-proline derivative | A proteinogenic amino acid derivative resulting from reaction of L-proline at the amino group or the carboxy group, or from the replacement of any hydrogen of L-proline by a heteroatom. |
| non-proteinogenic L-alpha-amino acid | Any L-alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (30.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.13) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||